Upanib 15 mg (Upadacitinib) Tablets

Upanib 15 mg (Upadacitinib) is a prescription medicine that selectively inhibits Janus kinase 1 (JAK1) to help regulate abnormal immune responses associated with chronic inflammatory diseases. It is prescribed by healthcare professionals for appropriate patients based on their clinical condition.

Therapeutic Uses

• Rheumatoid arthritis (RA)
• Psoriatic arthritis (PsA)
• Ankylosing spondylitis (AS)
• Non-radiographic axial spondyloarthritis (nr-axSpA)
• Atopic dermatitis (eczema)
• Ulcerative colitis (UC)
• Crohn's disease (CD)

Therapeutic Effects

• Helps reduce inflammation
• Relieves joint pain and stiffness
• Improves physical function and mobility
• Reduces skin inflammation and itching
• Supports remission in selected inflammatory bowel diseases
• Helps improve overall quality of life in eligible patients

Active Ingredient

Upadacitinib INN

Strength

15 mg per tablet

Dosage Form

Extended-Release Tablet

Pharmacological Class

Selective Janus Kinase 1 (JAK1) Inhibitor

Composition

Each extended-release tablet contains:

• Upadacitinib INN 15 mg (Active Pharmaceutical Ingredient)
• Pharmaceutical excipients sufficient to manufacture the tablet (inactive ingredients may vary by manufacturer). 

Important: Use this medicine only under the supervision of a qualified healthcare professional.

Recommended Adult Dose

• The usual recommended dose is 15 mg once daily, or as directed by the treating physician.
• The prescribed dose may vary depending on the medical condition, treatment response, and individual patient factors.

How to Take

• Swallow the tablet whole with water.
• Do not crush, chew, or split the tablet.
• It may be taken with or without food.
• Take the medicine at approximately the same time each day.

Missed Dose

• If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose.
• Do not take two doses at the same time to make up for a missed dose.

Important Administration Advice

• Continue treatment exactly as prescribed.
• Regular monitoring may be required during therapy.
• Do not stop treatment without consulting your healthcare provider.
• Follow all laboratory monitoring and follow-up appointments recommended by your physician.